The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Beyond the bevacizumab resistance, combined effects of erlotinib in heavily pretreated patients with recurrent ovarian cancers.
Yoshihiro Kikuchi
No relevant relationships to disclose
Masashi Takano
No relevant relationships to disclose
Yuji Ikeda
No relevant relationships to disclose
Ryoko Kikuchi
No relevant relationships to disclose
Kazuya Kudoh
No relevant relationships to disclose
Naoki Sasaki
No relevant relationships to disclose
Masaru Sakamoto
No relevant relationships to disclose
Tsunekazu Kita
No relevant relationships to disclose
Yasuhisa Terao
No relevant relationships to disclose
Satoru Takeda
No relevant relationships to disclose